All reports

All KCE reports are available in Dutch, French and English under several formats. Form and language of the reports

Publication year:
General domain:
Specific domain:

  1. [An evaluation procedure for the emerging medical technologies]

    KCE Reports 44 (2006)

    https://kce.fgov.be/en/an-evaluation-procedure-for-the-emerging-medical-technologies

  2. [Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium]

    KCE Reports 157 (2011)

    https://kce.fgov.be/en/economic-evaluation-of-antiviral-treatment-of-chronic-hepatitis-b-in-belgium

  3. [Fatigue Syndrome: diagnosis, treatment and organisation of care]

    KCE Reports 88 (2008)

    https://kce.fgov.be/en/fatigue-syndrome-diagnosis-treatment-and-organisation-of-care
  4. Hepatitis C: Screening en Preventie

    [Hepatitis C: Screening and Prevention]

    KCE Reports 173 (2012)

    https://kce.fgov.be/en/hepatitis-c-screening-and-prevention

  5. [Vaccine safety surveillance in Belgium : place and limits of a background rate approach]

    KCE Reports 188 (2012)

    https://kce.fgov.be/en/vaccine-safety-surveillance-in-belgium-place-and-limits-of-a-background-rate-approach

  6. A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study

    KCE Reports 231 (2014)

    https://kce.fgov.be/en/a-quadrivalent-vaccine-against-serogroup-b-meningococcal-disease-a-cost-effectiveness-study
  7. R183

    Belgian guidelines for economic evaluations and budget impact analyses: second edition

    KCE Reports 183 (2012)

    https://kce.fgov.be/en/belgian-guidelines-for-economic-evaluations-and-budget-impact-analyses-second-edition

  8. Cervical and lumbar total disc replacements

    KCE Reports 254 (2015)

    https://kce.fgov.be/en/cervical-and-lumbar-total-disc-replacements

  9. Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening

    KCE Reports 238 (2015)

    https://kce.fgov.be/en/cervical-cancer-screening-program-and-human-papillomavirus-hpv-testing-part-ii-update-on-hpv-primary
  10. Children in a playground

    Cost-effectiveness analysis of HPV vaccination of boys in Belgium

    KCE Reports 308 (2019) The vaccine for the human papilloma virus (HPV) which causes cervical cancer was introduced about ten years ago in Belgium, but only girls benefit from it. However, it is now established that this same virus is also involved in other cancers, including throat cancer. The recommendations have thus been reviewed and here, as in most western countries, it is now recommended to vaccinate boys too.

    https://kce.fgov.be/en/cost-effectiveness-analysis-of-hpv-vaccination-of-boys-in-belgium

  11. Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood

    KCE Reports 155 (2011)

    https://kce.fgov.be/en/cost-effectiveness-of-10-and-13-valent-pneumococcal-conjugate-vaccines-in-childhood

  12. Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium. Part 1: Literature review and results of a national study

    KCE Reports 127 (2010)

    https://kce.fgov.be/en/cost-effectiveness-of-antiviral-treatment-of-chronic-hepatitis-b-in-belgium-part-1-literature-review

  13. Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C

    KCE Reports 276 (2016)

    https://kce.fgov.be/en/economic-evaluation-of-novel-direct-acting-antiviral-daa-treatment-strategies-for-chronic-hepatitis
  14. R288

    How to improve the Belgian process for Managed Entry Agreements? An analysis of the Belgian and international experience

    KCE Reports 288 (2017)

    https://kce.fgov.be/en/how-to-improve-the-belgian-process-for-managed-entry-agreements-an-analysis-of-the-belgian-and

  15. HPV Vaccination for the Prevention of Cervical Cancer in Belgium: Health Technology Assessment

    KCE Reports 64 (2007)

    https://kce.fgov.be/en/hpv-vaccination-for-the-prevention-of-cervical-cancer-in-belgium-health-technology-assessment

  16. Novel serum biomarkers for the prediction of cardiovascular risk

    KCE Reports 201 (2013)

    https://kce.fgov.be/en/novel-serum-biomarkers-for-the-prediction-of-cardiovascular-risk

  17. Percutaneous Vertebroplasty and Balloon Kyphoplasty

    KCE Reports 255 (2015)

    https://kce.fgov.be/en/percutaneous-vertebroplasty-and-balloon-kyphoplasty

  18. Pharmaceutical and non-pharmaceutical interventions for Alzheimer’s Disease, a rapid assessment

    KCE Reports 111 (2009)

    https://kce.fgov.be/en/pharmaceutical-and-non-pharmaceutical-interventions-for-alzheimer%E2%80%99s-disease-a-rapid-assessment
  19. 3D printing illustration

    Responsible use of high-risk medical devices: the example of 3D printed medical devices

    KCE Reports 297 (2018) 3D printing is generating increased interest in the medical sector, namely in orthopaedics and dentistry, but there is no evidence that 3D-printed implants are as effective or safe as “classical” products. Yet they can currently be used without restrictions by doctors, even when they are “at high risk” (that is, more often than not, implantable).

    https://kce.fgov.be/en/responsible-use-of-high-risk-medical-devices-the-example-of-3d-printed-medical-devices

  20. Seasonal influenza vaccination: prioritizing children or other target groups? - Part II

    KCE Reports 204 (2013)

    https://kce.fgov.be/en/seasonal-influenza-vaccination-prioritizing-children-or-other-target-groups-part-ii

Pages